Literature DB >> 16734807

Rheologic behavior of sickle and normal red blood cell mixtures in sickle plasma: implications for transfusion therapy.

Tamas Alexy1, Eszter Pais, Jonathan K Armstrong, Herbert J Meiselman, Cage S Johnson, Timothy C Fisher.   

Abstract

BACKGROUND: Guidelines for transfusion in sickle cell disease usually define an upper hematocrit (Hct) limit of 0.30 to 0.35 to avoid blood hyperviscosity. In vitro viscosity studies of normal (AA) and sickle (SS) red blood cell (RBC) mixtures in buffer appear to confirm that this Hct limit is optimal for oxygen delivery to vascular beds as judged by the ratio of Hct to viscosity, with this ratio often termed "oxygen or RBC transport effectiveness." In the absence of plasma, however, effects due to RBC-RBC interactions mediated by plasma proteins cannot be assessed. STUDY DESIGNS AND METHODS: To investigate the optimal Hct-to-viscosity ratio of RBCs in plasma, the rheologic effects of Hct (0.20-0.40), the proportion of SS RBCs (0-100%), and shear rate (1-1000/sec) for mixtures of oxygenated and deoxygenated SS and AA RBCs were evaluated in sickle plasma at 37 degrees C.
RESULTS: RBC suspension viscosity was shear-dependent (i.e., viscosity decreased with increasing shear rate) and increased with Hct and proportion of SS RBCs. An "optimal" Hct level (defined as a maximal of the Hct-to-viscosity ratio) was seen only at shear rates above 50/sec. At lower shear rates (e.g., 5/sec), where plasma-mediated RBC-RBC interactions predominate, any increment in Hct was offset by a proportionally greater increase in viscosity, thus leading to a lower Hct-to-viscosity ratio.
CONCLUSION: These results indicate the importance of plasma-mediated RBC interactions and suggest that the benefits of transfusion may vary depending on local flow rates (i.e., shear rates) and organ-specific hemodynamics.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16734807     DOI: 10.1111/j.1537-2995.2006.00823.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  15 in total

1.  Sickle cell vasoocclusion and rescue in a microfluidic device.

Authors:  J M Higgins; D T Eddington; S N Bhatia; L Mahadevan
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-12       Impact factor: 11.205

2.  Sickle cell disease: selected aspects of pathophysiology.

Authors:  T Alexy; S Sangkatumvong; P Connes; E Pais; J Tripette; J C Barthelemy; T C Fisher; H J Meiselman; M C Khoo; T D Coates
Journal:  Clin Hemorheol Microcirc       Date:  2010       Impact factor: 2.375

3.  Quantifying the Cerebral Hemometabolic Response to Blood Transfusion in Pediatric Sickle Cell Disease With Diffuse Optical Spectroscopies.

Authors:  Seung Yup Lee; Rowan O Brothers; Katherine B Turrentine; Ayesha Quadri; Eashani Sathialingam; Kyle R Cowdrick; Scott Gillespie; Shasha Bai; Adam E Goldman-Yassen; Clinton H Joiner; R Clark Brown; Erin M Buckley
Journal:  Front Neurol       Date:  2022-07-01       Impact factor: 4.086

4.  Low-shear red blood cell oxygen transport effectiveness is adversely affected by transfusion and further worsened by deoxygenation in sickle cell disease patients on chronic transfusion therapy.

Authors:  Jon Detterich; Tamas Alexy; Miklos Rabai; Rosalinda Wenby; Ani Dongelyan; Thomas Coates; John Wood; Herbert Meiselman
Journal:  Transfusion       Date:  2012-08-06       Impact factor: 3.157

5.  Red blood cell aggregation, aggregate strength and oxygen transport potential of blood are abnormal in both homozygous sickle cell anemia and sickle-hemoglobin C disease.

Authors:  Julien Tripette; Tamas Alexy; Marie-Dominique Hardy-Dessources; Daniele Mougenel; Eric Beltan; Tawfik Chalabi; Roger Chout; Maryse Etienne-Julan; Olivier Hue; Herbert J Meiselman; Philippe Connes
Journal:  Haematologica       Date:  2009-08       Impact factor: 9.941

6.  Simple chronic transfusion therapy, a crucial therapeutic option for sickle cell disease, improves but does not normalize blood rheology: What should be our goals for transfusion therapy?

Authors:  Jon A Detterich
Journal:  Clin Hemorheol Microcirc       Date:  2018       Impact factor: 2.375

7.  Patients with sickle cell anemia on simple chronic transfusion protocol show sex differences for hemodynamic and hematologic responses to transfusion.

Authors:  Jon A Detterich; Suvimol Sangkatumvong; Roberta Kato; Ani Dongelyan; Adam Bush; Michael Khoo; Herbert J Meiselman; Thomas D Coates; John C Wood
Journal:  Transfusion       Date:  2012-11-26       Impact factor: 3.157

8.  Hemorheology and microvascular disorders.

Authors:  Young-Il Cho; Daniel J Cho
Journal:  Korean Circ J       Date:  2011-06-30       Impact factor: 3.243

9.  American Society of Hematology 2020 guidelines for sickle cell disease: prevention, diagnosis, and treatment of cerebrovascular disease in children and adults.

Authors:  M R DeBaun; L C Jordan; A A King; J Schatz; E Vichinsky; C K Fox; R C McKinstry; P Telfer; M A Kraut; L Daraz; F J Kirkham; M H Murad
Journal:  Blood Adv       Date:  2020-04-28

10.  Blood viscosity and the expression of inflammatory and adhesion markers in homozygous sickle cell disease subjects with chronic leg ulcers.

Authors:  Andre S Bowers; Harvey L Reid; Andre Greenidge; Clive Landis; Marvin Reid
Journal:  PLoS One       Date:  2013-07-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.